SIMILAR PATTERNS OF AMINO ACIDS FOR 5Y80_A_IREA401

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	VAL A 209 ALA A 220 GLU A 236 THR A 266 GLY A 272 LEU A 321 ASP A 332	None	0.63A	5y80A-1k9aA: 23.8	5y80A-1k9aA: 9.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.51A	5y80A-1opkA: 22.8	5y80A-1opkA: 10.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1q8y	SR PROTEIN KINASE (Saccharomyces cerevisiae)	PF00069 (Pkinase)	8	LEU A 164 VAL A 172 ALA A 185 LYS A 187 GLU A 202 GLY A 250 LEU A 301 ASP A 550	ADP A 810 ( 4.3A) ADP A 810 (-4.1A) ADP A 810 (-3.3A) ADP A 810 (-3.1A) None None ADP A 810 (-4.7A) ADP A 810 ( 3.0A)	0.95A	5y80A-1q8yA: 23.1	5y80A-1q8yA: 12.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 VAL A 624 ALA A 642 GLU A 661 CYH A 694 GLY A 697 LEU A 818 ASP A 829	None	0.75A	5y80A-1rjbA: 20.8	5y80A-1rjbA: 12.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 595 VAL A 603 ALA A 621 GLU A 640 THR A 670 CYH A 673 GLY A 676 LEU A 799	STI A 3 ( 3.8A) STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-3.6A) STI A 3 (-3.2A) STI A 3 (-4.5A) STI A 3 ( 3.8A) STI A 3 (-4.4A)	0.50A	5y80A-1t46A: 22.6	5y80A-1t46A: 12.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 595 VAL A 603 ALA A 621 LYS A 623 GLU A 640 THR A 670 CYH A 673 GLY A 676	STI A 3 ( 3.8A) STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-3.7A) STI A 3 (-3.6A) STI A 3 (-3.2A) STI A 3 (-4.5A) STI A 3 ( 3.8A)	0.59A	5y80A-1t46A: 22.6	5y80A-1t46A: 12.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 344 VAL A 352 ALA A 367 LYS A 369 GLU A 386 GLY A 420 LEU A 468 ASP A 479	STU A 100 (-3.8A) STU A 100 (-4.8A) STU A 100 (-3.2A) STU A 100 ( 4.7A) None STU A 100 (-3.5A) STU A 100 (-4.5A) STU A 100 (-3.5A)	0.52A	5y80A-1u59A: 23.7	5y80A-1u59A: 12.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u5q	SERINE/THREONINE PROTEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	8	VAL A 42 ALA A 55 LYS A 57 GLU A 76 CYH A 108 GLY A 110 LEU A 158 ASP A 169	None	0.55A	5y80A-1u5qA: 24.4	5y80A-1u5qA: 10.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 15 VAL A 23 ALA A 36 GLU A 55 CYH A 87 GLY A 90 LEU A 137 ASP A 148	HYM A 400 (-4.2A) HYM A 400 (-4.3A) HYM A 400 (-3.5A) None HYM A 400 (-4.2A) None HYM A 400 (-4.5A) HYM A 400 (-3.9A)	0.55A	5y80A-1zltA: 23.1	5y80A-1zltA: 12.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2a2a	DEATH-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 19 VAL A 27 ALA A 40 LYS A 42 GLU A 64 LEU A 95 ASP A 161	None None GOL A3001 (-3.5A) None None None None	0.63A	5y80A-2a2aA: 25.9	5y80A-2a2aA: 13.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2buj	SERINE/THREONINE-PRO TEIN KINASE 16 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 26 VAL A 34 ALA A 47 LYS A 49 GLU A 65 GLY A 104 LEU A 155	STU A1301 (-4.2A) STU A1301 (-4.8A) STU A1301 (-3.6A) STU A1301 ( 4.0A) None STU A1301 ( 4.0A) STU A1301 ( 4.8A)	0.62A	5y80A-2bujA: 29.7	5y80A-2bujA: 11.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU X 17 VAL X 25 ALA X 37 LYS X 39 GLU X 54 THR X 82 GLY X 88 LEU X 137 ASP X 148	STU X 902 (-3.8A) STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-3.1A) STU X 902 ( 4.4A) STU X 902 (-4.1A) STU X 902 (-3.5A) STU X 902 (-4.4A) STU X 902 (-3.6A)	0.61A	5y80A-2dq7X: 24.2	5y80A-2dq7X: 16.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	9	LEU A 162 VAL A 170 ALA A 184 LYS A 186 GLU A 201 LEU A 238 GLY A 240 LEU A 290 ASP A 320	None	0.88A	5y80A-2eu9A: 24.5	5y80A-2eu9A: 11.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2gcd	SERINE/THREONINE-PRO TEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	8	VAL A 42 ALA A 55 LYS A 57 GLU A 76 CYH A 108 GLY A 110 LEU A 158 ASP A 169	STU A 400 ( 4.8A) STU A 400 (-3.2A) STU A 400 ( 4.5A) None STU A 400 (-4.0A) STU A 400 (-3.4A) STU A 400 ( 4.6A) STU A 400 (-3.6A)	0.45A	5y80A-2gcdA: 24.3	5y80A-2gcdA: 9.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 273 VAL A 281 ALA A 293 THR A 338 GLY A 344 LEU A 393 ASP A 404	H8H A 534 (-3.8A) H8H A 534 (-4.4A) H8H A 534 (-3.2A) H8H A 534 (-3.1A) H8H A 534 (-3.3A) H8H A 534 (-4.5A) H8H A 534 (-4.2A)	0.63A	5y80A-2h8hA: 21.7	5y80A-2h8hA: 11.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 248 VAL A 256 ALA A 269 GLU A 286 THR A 315 GLY A 321 LEU A 370 ASP A 381	GIN A 600 ( 4.6A) GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.4A) None GIN A 600 (-4.7A) GIN A 600 (-4.9A)	0.64A	5y80A-2hz0A: 22.8	5y80A-2hz0A: 14.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 248 VAL A 256 ALA A 269 LYS A 271 GLU A 286 THR A 315 GLY A 321 ASP A 381	GIN A 600 ( 4.6A) GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.6A) GIN A 600 (-3.4A) None GIN A 600 (-4.9A)	0.78A	5y80A-2hz0A: 22.8	5y80A-2hz0A: 14.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2j0j	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF00373 (FERM_M) PF07714 (Pkinase_Tyr)	9	VAL A 436 ALA A 452 LYS A 454 GLU A 471 LEU A 501 CYH A 502 GLY A 505 LEU A 553 ASP A 564	4ST A1687 ( 4.8A) 4ST A1687 (-3.3A) 4ST A1687 (-3.4A) 4ST A1687 ( 4.6A) 4ST A1687 (-4.3A) 4ST A1687 (-4.1A) 4ST A1687 (-3.2A) 4ST A1687 (-4.4A) 4ST A1687 (-4.7A)	0.60A	5y80A-2j0jA: 23.2	5y80A-2j0jA: 9.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 251 VAL A 259 ALA A 271 LYS A 273 GLU A 288 THR A 316 GLY A 322 LEU A 371	None None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.6A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.5A) 1N8 A 501 ( 4.3A)	0.85A	5y80A-2og8A: 21.6	5y80A-2og8A: 18.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 588 VAL A 596 ALA A 614 GLU A 633 THR A 663 CYH A 666 GLY A 669 LEU A 785 ASP A 796	None	0.86A	5y80A-2ogvA: 21.2	5y80A-2ogvA: 11.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	9	LEU A 25 VAL A 33 ALA A 46 LYS A 48 GLU A 73 LEU A 105 GLY A 109 LEU A 156 ASP A 167	ATP A 381 ( 4.3A) ATP A 381 (-4.1A) ATP A 381 (-3.5A) ATP A 381 (-3.2A) None None None ATP A 381 ( 4.8A) MN A 382 (-2.0A)	0.64A	5y80A-2phkA: 27.1	5y80A-2phkA: 14.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 724 VAL A 732 ALA A 749 THR A 796 LEU A 798 GLY A 802 LEU A 850 ASP A 861	GW7 A 1 ( 4.2A) GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-4.0A) GW7 A 1 (-4.5A) GW7 A 1 (-3.6A) GW7 A 1 (-4.2A) GW7 A 1 (-4.1A)	0.63A	5y80A-2r4bA: 20.7	5y80A-2r4bA: 12.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2w4k	DEATH-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 19 VAL A 27 ALA A 40 LYS A 42 GLU A 64 LEU A 95 ASP A 161	ADP A1303 ( 3.9A) ADP A1303 (-4.0A) ADP A1303 (-3.5A) ADP A1303 (-2.7A) ADP A1303 ( 4.8A) None MG A1304 ( 2.8A)	0.55A	5y80A-2w4kA: 25.8	5y80A-2w4kA: 16.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2wnt	RIBOSOMAL PROTEIN S6 KINASE (Homo sapiens)	PF00069 (Pkinase)	8	ALA A 445 LYS A 447 GLU A 459 THR A 489 LEU A 491 GLY A 495 LEU A 542 ASP A 557	None	0.78A	5y80A-2wntA: 22.0	5y80A-2wntA: 13.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xik	SERINE/THREONINE PROTEIN KINASE 25 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 34 ALA A 47 LYS A 49 GLU A 66 GLY A 101 LEU A 147 ASP A 158	J60 A1294 ( 4.9A) J60 A1294 (-3.3A) None None J60 A1294 ( 3.8A) J60 A1294 (-4.8A) J60 A1294 ( 4.6A)	0.62A	5y80A-2xikA: 25.1	5y80A-2xikA: 14.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2yab	DEATH-ASSOCIATED PROTEIN KINASE 2 (Mus musculus)	PF00069 (Pkinase)	7	LEU A 19 VAL A 27 ALA A 40 LYS A 42 GLU A 64 LEU A 95 ASP A 161	AMP A1302 (-3.7A) AMP A1302 (-4.2A) AMP A1302 (-3.6A) AMP A1302 (-2.8A) None AMP A1302 ( 4.9A) AMP A1302 (-3.1A)	0.55A	5y80A-2yabA: 26.1	5y80A-2yabA: 13.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 68 VAL A 76 ALA A 92 LYS A 94 GLY A 147 LEU A 194 ASP A 205	STU A 1 (-3.8A) None STU A 1 (-3.3A) STU A 1 (-2.8A) STU A 1 ( 3.9A) STU A 1 (-4.6A) STU A 1 ( 3.8A)	0.54A	5y80A-2z7rA: 23.3	5y80A-2z7rA: 16.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3a62	RIBOSOMAL PROTEIN S6 KINASE BETA-1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 97 VAL A 105 ALA A 121 LYS A 123 GLU A 143 GLY A 178 ASP A 236	STU A 400 (-3.8A) STU A 400 (-4.9A) STU A 400 (-3.1A) STU A 400 ( 4.3A) STU A 400 ( 4.3A) STU A 400 ( 4.4A) STU A 400 ( 3.8A)	0.60A	5y80A-3a62A: 6.5	5y80A-3a62A: 13.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 484 VAL A 492 ALA A 512 LYS A 514 GLU A 531 GLY A 567 LEU A 630 ASP A 641	C4F A 1 ( 3.9A) None C4F A 1 (-3.3A) None None None C4F A 1 (-4.6A) C4F A 1 (-4.5A)	0.81A	5y80A-3c4fA: 21.6	5y80A-3c4fA: 12.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 209 ALA A 220 GLU A 236 THR A 266 GLY A 272 LEU A 321 ASP A 332	None	0.63A	5y80A-3d7uA: 24.4	5y80A-3d7uA: 13.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hko	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 2 CALMODULIN-LIKE EF HANDS (Cryptosporidium parvum)	PF00069 (Pkinase)	8	ALA A 37 LYS A 39 GLU A 60 LEU A 91 CYH A 92 GLY A 95 LEU A 182 ASP A 195	ANP A 329 ( 3.7A) ANP A 329 (-2.7A) MG A 330 ( 4.6A) ANP A 329 ( 4.7A) ANP A 329 (-4.1A) None ANP A 329 (-4.4A) MG A 330 ( 2.9A)	1.11A	5y80A-3hkoA: 23.6	5y80A-3hkoA: 14.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hko	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 2 CALMODULIN-LIKE EF HANDS (Cryptosporidium parvum)	PF00069 (Pkinase)	8	VAL A 24 ALA A 37 LYS A 39 GLU A 60 LEU A 91 CYH A 92 GLY A 94 LEU A 182	ANP A 329 (-4.4A) ANP A 329 ( 3.7A) ANP A 329 (-2.7A) MG A 330 ( 4.6A) ANP A 329 ( 4.7A) ANP A 329 (-4.1A) None ANP A 329 (-4.4A)	1.12A	5y80A-3hkoA: 23.6	5y80A-3hkoA: 14.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hko	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 2 CALMODULIN-LIKE EF HANDS (Cryptosporidium parvum)	PF00069 (Pkinase)	8	VAL A 24 ALA A 37 LYS A 39 GLU A 60 LEU A 91 CYH A 92 GLY A 95 LEU A 182	ANP A 329 (-4.4A) ANP A 329 ( 3.7A) ANP A 329 (-2.7A) MG A 330 ( 4.6A) ANP A 329 ( 4.7A) ANP A 329 (-4.1A) None ANP A 329 (-4.4A)	1.07A	5y80A-3hkoA: 23.6	5y80A-3hkoA: 14.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 833 VAL A 841 ALA A 859 LYS A 861 GLU A 878 CYH A 912 GLY A 915 LEU A1029	8ST A2001 ( 4.7A) 8ST A2001 ( 4.6A) 8ST A2001 ( 3.8A) 8ST A2001 (-4.0A) 8ST A2001 (-3.7A) 8ST A2001 (-3.8A) None None	0.66A	5y80A-3hngA: 22.0	5y80A-3hngA: 14.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kn5	RIBOSOMAL PROTEIN S6 KINASE ALPHA-5 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 432 ALA A 453 LYS A 455 GLU A 468 LEU A 500 LEU A 551 ASP A 565	ANP A 400 (-4.1A) ANP A 400 ( 3.8A) None None ANP A 400 (-4.6A) ANP A 400 (-4.7A) None	0.62A	5y80A-3kn5A: 22.1	5y80A-3kn5A: 14.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	8	VAL A 649 ALA A 665 LYS A 667 GLU A 684 THR A 713 GLY A 719 LEU A 767 ASP A 778	None None None None None GOL A 403 (-3.4A) None None	0.74A	5y80A-3kulA: 24.4	5y80A-3kulA: 12.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lj0	SERINE/THREONINE-PRO TEIN KINASE/ENDORIBONUCLE ASE IRE1 (Saccharomyces cerevisiae)	PF00069 (Pkinase) PF06479 (Ribonuc_2-5A)	8	LEU A 680 VAL A 689 ALA A 700 GLU A 715 LEU A 747 CYH A 748 LEU A 804 ASP A 828	ADP A2101 ( 4.1A) ADP A2101 (-4.5A) ADP A2101 (-3.5A) None None ADP A2101 (-4.2A) ADP A2101 (-4.4A) SR A2103 (-2.6A)	0.78A	5y80A-3lj0A: 24.1	5y80A-3lj0A: 12.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	8	VAL A 218 ALA A 229 LYS A 231 GLU A 244 THR A 279 GLY A 285 LEU A 339 ASP A 350	LDN A 1 ( 4.8A) LDN A 1 (-3.6A) None None LDN A 1 (-3.8A) LDN A 1 (-3.3A) LDN A 1 (-4.5A) LDN A 1 (-3.9A)	0.70A	5y80A-3mdyA: 24.0	5y80A-3mdyA: 14.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mvj	CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 49 VAL A 57 ALA A 70 LYS A 72 GLU A 91 GLY A 126 LEU A 173 ASP A 184	XFE A 351 (-4.2A) XFE A 351 ( 4.5A) XFE A 351 (-3.2A) None None None XFE A 351 (-4.6A) None	0.69A	5y80A-3mvjA: 24.0	5y80A-3mvjA: 12.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	8	LEU A 192 VAL A 200 ALA A 213 LYS A 215 GLU A 234 LEU A 265 GLY A 269 ASP A 329	AMP A 577 ( 4.3A) AMP A 577 (-4.3A) AMP A 577 (-3.4A) AMP A 577 (-2.8A) None AMP A 577 ( 4.9A) None AMP A 577 (-4.0A)	0.88A	5y80A-3nyoA: 23.9	5y80A-3nyoA: 8.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 726 VAL A 734 ALA A 751 LYS A 753 THR A 798 LEU A 800 GLY A 804 LEU A 852 ASP A 863	03Q A 1 (-3.8A) 03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.7A) 03Q A 1 (-4.1A) 03Q A 1 (-4.6A) 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A) 03Q A 1 (-4.0A)	0.78A	5y80A-3pp0A: 21.6	5y80A-3pp0A: 14.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	8	VAL A 565 ALA A 576 LYS A 578 GLU A 596 THR A 625 GLY A 631 LEU A 683 ASP A 694	STU A 1 (-4.9A) STU A 1 (-3.3A) STU A 1 (-3.5A) None STU A 1 (-4.1A) STU A 1 (-3.2A) STU A 1 (-4.3A) STU A 1 (-3.5A)	0.70A	5y80A-3ppzA: 24.8	5y80A-3ppzA: 13.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q5i	PROTEIN KINASE (Plasmodium berghei)	PF00069 (Pkinase) PF13499 (EF-hand_7)	8	LEU A 63 VAL A 71 ALA A 84 GLU A 115 THR A 144 GLY A 150 LEU A 197 ASP A 211	ANP A1634 ( 4.3A) ANP A1634 (-4.1A) ANP A1634 (-3.6A) None ANP A1634 (-4.6A) None ANP A1634 (-4.4A) MG A 529 (-2.2A)	0.69A	5y80A-3q5iA: 22.7	5y80A-3q5iA: 10.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q5i	PROTEIN KINASE (Plasmodium berghei)	PF00069 (Pkinase) PF13499 (EF-hand_7)	8	LEU A 63 VAL A 71 ALA A 84 LYS A 86 GLU A 115 GLY A 150 LEU A 197 ASP A 211	ANP A1634 ( 4.3A) ANP A1634 (-4.1A) ANP A1634 (-3.6A) ANP A1634 (-3.1A) None None ANP A1634 (-4.4A) MG A 529 (-2.2A)	0.77A	5y80A-3q5iA: 22.7	5y80A-3q5iA: 10.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3she	MAP KINASE-ACTIVATED PROTEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 50 VAL A 58 ALA A 71 LYS A 73 GLU A 84 GLY A 124 LEU A 173 ASP A 187	I85 A 350 (-3.7A) I85 A 350 (-4.9A) I85 A 350 (-3.3A) I85 A 350 (-2.8A) None I85 A 350 (-3.0A) None I85 A 350 (-3.3A)	0.80A	5y80A-3sheA: 21.8	5y80A-3sheA: 15.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 484 VAL A 492 ALA A 512 LYS A 514 GLU A 531 GLY A 567 LEU A 630 ASP A 641	07J A 1 ( 4.3A) 07J A 1 (-4.0A) 07J A 1 (-3.5A) 07J A 1 (-4.5A) 07J A 1 (-3.8A) 07J A 1 (-3.7A) 07J A 1 ( 4.4A) 07J A 1 (-4.7A)	0.69A	5y80A-3tt0A: 21.9	5y80A-3tt0A: 13.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3txo	PROTEIN KINASE C ETA TYPE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	8	LEU A 361 VAL A 369 ALA A 382 LYS A 384 GLU A 403 GLY A 439 LEU A 486 ASP A 497	07U A 1 ( 4.8A) 07U A 1 (-4.8A) 07U A 1 (-3.3A) 07U A 1 (-3.0A) 07U A 1 ( 4.8A) None 07U A 1 (-4.3A) 07U A 1 (-3.6A)	0.65A	5y80A-3txoA: 23.6	5y80A-3txoA: 12.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 840 VAL A 848 ALA A 866 LYS A 868 GLU A 885 CYH A 919 GLY A 922 LEU A1035	4TT A2001 ( 4.0A) 4TT A2001 ( 4.5A) 4TT A2001 (-3.5A) None None 4TT A2001 (-4.3A) 4TT A2001 (-3.7A) 4TT A2001 (-4.8A)	0.55A	5y80A-3vidA: 21.0	5y80A-3vidA: 12.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 840 VAL A 848 ALA A 866 LYS A 868 GLU A 885 CYH A 919 GLY A 922 LEU A1035 ASP A1046	LEV A1201 ( 3.8A) LEV A1201 ( 4.9A) LEV A1201 (-3.5A) None LEV A1201 (-3.7A) LEV A1201 (-4.1A) LEV A1201 (-3.6A) LEV A1201 (-4.8A) GOL A1210 ( 3.4A)	0.74A	5y80A-3wzdA: 21.3	5y80A-3wzdA: 13.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4a4l	SERINE/THREONINE-PRO TEIN KINASE PLK1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 59 ALA A 80 LYS A 82 GLU A 101 LEU A 132 CYH A 133 ASP A 194	939 A1331 (-3.7A) 939 A1331 (-3.5A) 939 A1331 (-2.6A) None 939 A1331 (-4.4A) 939 A1331 (-4.0A) 939 A1331 (-3.1A)	0.62A	5y80A-4a4lA: 27.9	5y80A-4a4lA: 12.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4aw2	SERINE/THREONINE-PRO TEIN KINASE MRCK ALPHA (Rattus norvegicus)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	VAL A 91 ALA A 104 LYS A 106 GLU A 125 GLY A 160 LEU A 208 ASP A 219	None EDO A1420 (-3.4A) EDO A1419 (-3.3A) EDO A1419 (-3.0A) None EDO A1420 ( 4.8A) None	0.58A	5y80A-4aw2A: 23.8	5y80A-4aw2A: 11.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c0t	LIKELY PROTEIN KINASE (Candida albicans)	PF00069 (Pkinase)	8	LEU A 246 VAL A 254 ALA A 267 LYS A 269 GLU A 288 GLY A 324 LEU A 371 ASP A 382	None	0.73A	5y80A-4c0tA: 25.8	5y80A-4c0tA: 6.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4cfh	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1 (Rattus norvegicus)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	7	VAL A 30 ALA A 43 LYS A 45 GLU A 64 GLY A 99 LEU A 146 ASP A 157	None STU A1550 (-3.1A) STU A1550 (-3.6A) None STU A1550 (-3.4A) STU A1550 (-4.3A) STU A1550 (-3.6A)	0.61A	5y80A-4cfhA: 25.6	5y80A-4cfhA: 9.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 VAL A 624 ALA A 653 LYS A 655 GLU A 672 THR A 701 GLY A 707 LEU A 773	None DI1 A1000 (-4.8A) DI1 A1000 (-3.6A) DI1 A1000 (-3.9A) DI1 A1000 (-3.8A) DI1 A1000 (-3.6A) None DI1 A1000 (-4.5A)	0.73A	5y80A-4ckrA: 21.9	5y80A-4ckrA: 13.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	8	LEU A 663 VAL A 671 ALA A 684 LYS A 686 GLU A 705 GLY A 743 LEU A 789 ASP A 800	AGS A1985 (-4.2A) AGS A1985 (-4.6A) AGS A1985 (-3.5A) AGS A1985 (-3.0A) None None AGS A1985 (-4.8A) AGS A1985 ( 3.3A)	0.66A	5y80A-4crsA: 25.8	5y80A-4crsA: 12.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4eut	SERINE/THREONINE-PRO TEIN KINASE TBK1 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 15 VAL A 23 ALA A 36 LYS A 38 GLU A 55 CYH A 89 GLY A 92 ASP A 157	BX7 A 401 (-3.7A) BX7 A 401 (-4.4A) BX7 A 401 (-3.4A) BX7 A 401 ( 4.0A) None BX7 A 401 (-4.1A) BX7 A 401 (-3.5A) BX7 A 401 ( 3.7A)	0.72A	5y80A-4eutA: 20.6	5y80A-4eutA: 12.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4euu	SERINE/THREONINE-PRO TEIN KINASE TBK1 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 15 VAL A 23 ALA A 36 LYS A 38 GLU A 55 CYH A 89 GLY A 92 ASP A 157	BX7 A 401 (-3.9A) BX7 A 401 ( 4.6A) BX7 A 401 (-3.4A) BX7 A 401 (-3.5A) None BX7 A 401 (-4.1A) BX7 A 401 (-3.3A) BX7 A 401 (-3.6A)	0.60A	5y80A-4euuA: 22.6	5y80A-4euuA: 15.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A1122 VAL A1130 ALA A1148 GLU A1167 LEU A1198 GLY A1202 LEU A1256 ASP A1270	0UV A1501 (-3.8A) 0UV A1501 (-4.5A) 0UV A1501 (-3.4A) None 0UV A1501 ( 4.8A) 0UV A1501 (-3.6A) 0UV A1501 (-4.6A) 0UV A1501 ( 4.2A)	0.90A	5y80A-4fodA: 22.2	5y80A-4fodA: 11.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fr4	SERINE/THREONINE-PRO TEIN KINASE 32A (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 37 ALA A 50 LYS A 52 GLU A 71 LEU A 102 GLY A 106 LEU A 153 ASP A 164	STU A 401 ( 4.9A) STU A 401 (-3.2A) None None STU A 401 (-4.4A) STU A 401 ( 3.7A) STU A 401 (-4.7A) STU A 401 ( 3.9A)	0.55A	5y80A-4fr4A: 23.6	5y80A-4fr4A: 13.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4g3f	NF-KAPPA-BETA-INDUCI NG KINASE (Mus musculus)	PF00069 (Pkinase)	8	VAL A 416 ALA A 429 LYS A 431 GLU A 442 LEU A 473 GLY A 477 LEU A 524 ASP A 536	0WB A 701 (-4.4A) 0WB A 701 (-3.3A) 0WB A 701 (-3.0A) 0WB A 701 (-3.2A) 0WB A 701 (-4.3A) 0WB A 701 ( 4.5A) 0WB A 701 (-4.3A) 0WB A 701 (-3.1A)	0.65A	5y80A-4g3fA: 21.2	5y80A-4g3fA: 15.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	8	LEU A 855 VAL A 863 ALA A 880 LYS A 882 GLU A 898 GLY A 935 LEU A 983 ASP A 994	IZA A2001 (-3.7A) None IZA A2001 (-3.4A) IZA A2001 ( 4.7A) None IZA A2001 (-3.3A) IZA A2001 ( 4.7A) IZA A2001 ( 4.5A)	0.76A	5y80A-4gl9A: 24.3	5y80A-4gl9A: 15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 828 VAL A 836 ALA A 853 LYS A 855 GLU A 871 GLY A 908 LEU A 956 ASP A 967	19S A1201 (-3.9A) 19S A1201 (-4.4A) 19S A1201 (-3.3A) 19S A1201 (-3.5A) None 19S A1201 ( 3.8A) 19S A1201 (-4.5A) 19S A1201 ( 4.1A)	0.67A	5y80A-4hviA: 24.2	5y80A-4hviA: 16.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	8	LEU A 132 VAL A 140 ALA A 156 THR A 205 LEU A 207 GLY A 211 LEU A 259 ASP A 270	None	0.80A	5y80A-4hzsA: 19.9	5y80A-4hzsA: 14.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 132 VAL A 140 ALA A 156 THR A 205 LEU A 207 GLY A 211 LEU A 259	1G0 A 401 ( 4.5A) 1G0 A 401 (-4.4A) 1G0 A 401 (-3.6A) 1G0 A 401 (-3.2A) 1G0 A 401 ( 4.9A) 1G0 A 401 ( 4.5A) 1G0 A 401 (-4.6A)	0.62A	5y80A-4id7A: 23.8	5y80A-4id7A: 14.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4idt	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 406 VAL A 414 ALA A 427 GLU A 440 LEU A 471 GLY A 475 LEU A 522 ASP A 534	T28 A 701 (-3.8A) T28 A 701 (-4.7A) T28 A 701 (-3.0A) None T28 A 701 ( 4.8A) T28 A 701 ( 3.0A) T28 A 701 (-3.9A) T28 A 701 ( 3.4A)	0.80A	5y80A-4idtA: 21.5	5y80A-4idtA: 13.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4idt	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 406 VAL A 414 ALA A 427 LYS A 429 GLU A 440 LEU A 471 GLY A 475 ASP A 534	T28 A 701 (-3.8A) T28 A 701 (-4.7A) T28 A 701 (-3.0A) T28 A 701 ( 3.8A) None T28 A 701 ( 4.8A) T28 A 701 ( 3.0A) T28 A 701 ( 3.4A)	0.99A	5y80A-4idtA: 21.5	5y80A-4idtA: 13.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jlc	SERINE/THREONINE-PRO TEIN KINASE TBK1 (Mus musculus)	PF00069 (Pkinase)	7	LEU A 15 VAL A 23 ALA A 36 LYS A 38 CYH A 89 GLY A 92 ASP A 157	SU6 A 701 (-3.6A) None SU6 A 701 (-3.4A) None SU6 A 701 (-3.8A) SU6 A 701 (-3.8A) None	0.54A	5y80A-4jlcA: 6.0	5y80A-4jlcA: 7.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jxf	SERINE/THREONINE-PRO TEIN KINASE PLK4 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 18 VAL A 26 ALA A 39 LYS A 41 CYH A 92 GLY A 95 LEU A 143	631 A 301 (-3.4A) 631 A 301 (-4.6A) 631 A 301 (-3.3A) 631 A 301 (-2.7A) 631 A 301 (-4.5A) 631 A 301 ( 3.7A) 631 A 301 (-4.0A)	0.53A	5y80A-4jxfA: 18.8	5y80A-4jxfA: 12.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4mvf	CALCIUM-DEPENDENT PROTEIN KINASE 2 (Plasmodium falciparum)	PF00069 (Pkinase) PF13499 (EF-hand_7)	10	LEU A 78 VAL A 86 ALA A 99 LYS A 101 GLU A 117 LEU A 148 CYH A 149 GLY A 151 LEU A 199 ASP A 213	STU A 601 ( 4.0A) STU A 601 (-4.8A) STU A 601 (-3.3A) STU A 601 (-3.9A) None STU A 601 (-4.3A) STU A 601 (-4.2A) STU A 601 (-3.4A) STU A 601 (-4.7A) STU A 601 (-4.3A)	0.88A	5y80A-4mvfA: 23.0	5y80A-4mvfA: 11.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	9	ALA A 67 GLU A 85 THR A 123 LEU A 125 CYH A 126 GLY A 128 GLN A 129 LEU A 180 ASP A 191	SIN A 401 ( 3.7A) None None SIN A 401 ( 4.8A) SIN A 401 (-4.3A) SIN A 401 (-3.5A) None SIN A 401 ( 4.5A) None	0.67A	5y80A-4o38A: 34.1	5y80A-4o38A: 90.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	10	LEU A 46 VAL A 54 ALA A 67 GLU A 85 THR A 123 LEU A 125 CYH A 126 GLY A 128 LEU A 180 ASP A 191	SIN A 401 ( 3.9A) None SIN A 401 ( 3.7A) None None SIN A 401 ( 4.8A) SIN A 401 (-4.3A) SIN A 401 (-3.5A) SIN A 401 ( 4.5A) None	0.47A	5y80A-4o38A: 34.1	5y80A-4o38A: 90.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	10	LEU A 46 VAL A 54 ALA A 67 LYS A 69 GLU A 85 THR A 123 LEU A 125 CYH A 126 GLY A 128 ASP A 191	SIN A 401 ( 3.9A) None SIN A 401 ( 3.7A) None None None SIN A 401 ( 4.8A) SIN A 401 (-4.3A) SIN A 401 (-3.5A) None	0.57A	5y80A-4o38A: 34.1	5y80A-4o38A: 90.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 903 VAL A 911 ALA A 928 LYS A 930 GLU A 947 GLY A 984 LEU A1030 ASP A1041	2TT A1202 (-3.5A) 2TT A1202 (-4.5A) 2TT A1202 ( 3.9A) None None 2TT A1202 (-3.4A) 2TT A1202 (-4.4A) 2TT A1202 (-4.6A)	0.72A	5y80A-4oliA: 6.3	5y80A-4oliA: 8.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 616 VAL A 624 ALA A 642 GLU A 661 CYH A 694 GLY A 697 LEU A 818	P30 A1001 (-3.8A) None P30 A1001 (-3.4A) P30 A1001 (-3.6A) None P30 A1001 (-3.4A) P30 A1001 (-4.6A)	0.49A	5y80A-4rt7A: 22.3	5y80A-4rt7A: 10.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wb7	DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase) PF00226 (DnaJ)	8	LEU A 104 VAL A 112 ALA A 125 LYS A 127 GLU A 146 GLY A 181 LEU A 228 ASP A 239	ATP A 501 ( 4.3A) ATP A 501 (-4.0A) ATP A 501 (-3.4A) ATP A 501 (-2.6A) None None ATP A 501 (-4.5A) ZN A 503 (-1.9A)	0.68A	5y80A-4wb7A: 24.3	5y80A-4wb7A: 12.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	9	LEU A 52 VAL A 60 ALA A 72 LYS A 74 CYH A 129 GLY A 132 GLN A 133 LEU A 183 ASP A 194	KSA A 405 ( 4.0A) KSA A 405 ( 4.9A) KSA A 405 (-3.2A) None KSA A 405 (-4.5A) KSA A 405 (-3.5A) KSA A 405 (-3.2A) KSA A 405 (-4.6A) ZN A 403 ( 2.6A)	0.81A	5y80A-4wsqA: 32.5	5y80A-4wsqA: 25.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	9	LEU A 52 VAL A 60 ALA A 72 LYS A 74 GLU A 90 CYH A 129 GLY A 132 LEU A 183 ASP A 194	KSA A 405 ( 4.0A) KSA A 405 ( 4.9A) KSA A 405 (-3.2A) None None KSA A 405 (-4.5A) KSA A 405 (-3.5A) KSA A 405 (-4.6A) ZN A 403 ( 2.6A)	0.67A	5y80A-4wsqA: 32.5	5y80A-4wsqA: 25.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 VAL A 624 ALA A 642 LYS A 644 GLU A 661 CYH A 694 GLY A 697 LEU A 818	P30 A1001 (-4.0A) P30 A1001 ( 4.8A) P30 A1001 (-3.5A) P30 A1001 ( 4.0A) P30 A1001 (-3.1A) P30 A1001 (-4.2A) P30 A1001 (-3.5A) P30 A1001 (-4.3A)	0.63A	5y80A-4xufA: 21.9	5y80A-4xufA: 12.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 477 ALA A 488 LYS A 490 GLU A 509 THR A 539 GLY A 545 LEU A 595	None 4CV A 801 (-3.5A) 4CV A 801 (-3.9A) None 4CV A 801 (-2.8A) 4CV A 801 ( 4.0A) 4CV A 801 (-4.4A)	0.59A	5y80A-4yffA: 23.2	5y80A-4yffA: 12.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ysj	CALMODULIN-LIKE DOMAIN PROTEIN KINASE (Eimeria tenella)	PF00069 (Pkinase) PF13499 (EF-hand_7)	9	LEU A 34 VAL A 42 ALA A 55 LYS A 57 GLU A 76 THR A 105 GLY A 111 LEU A 158 ASP A 172	ADP A 506 ( 3.8A) ADP A 506 (-4.3A) ADP A 506 (-3.3A) ADP A 506 (-2.4A) None ADP A 506 ( 4.6A) None ADP A 506 (-4.7A) ADP A 506 ( 2.4A)	0.84A	5y80A-4ysjA: 25.1	5y80A-4ysjA: 12.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ezr	CGMP-DEPENDENT PROTEIN KINASE, PUTATIVE (Plasmodium vivax)	PF00027 (cNMP_binding) PF00069 (Pkinase)	7	VAL A 548 ALA A 561 LYS A 563 THR A 611 LEU A 613 LEU A 664 ASP A 675	4ZS A 901 (-4.8A) 4ZS A 901 ( 3.8A) 4ZS A 901 (-3.9A) 4ZS A 901 (-3.2A) 4ZS A 901 (-4.7A) 4ZS A 901 (-3.6A) None	0.57A	5y80A-5ezrA: 23.5	5y80A-5ezrA: 7.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 903 VAL A 911 ALA A 928 LYS A 930 GLU A 947 GLY A 984 LEU A1030 ASP A1041	5U3 A1200 (-3.8A) 5U3 A1200 ( 4.4A) 5U3 A1200 (-3.5A) None None 5U3 A1200 (-3.2A) 5U3 A1200 (-4.4A) 5U3 A1200 ( 4.9A)	0.85A	5y80A-5f1zA: 22.7	5y80A-5f1zA: 14.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 599 VAL A 607 ALA A 625 GLU A 644 THR A 674 CYH A 677 GLY A 680 LEU A 825	748 A1001 (-3.8A) 748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 (-3.3A) 748 A1001 (-3.2A) 748 A1001 (-4.5A) 748 A1001 ( 4.0A) 748 A1001 (-4.3A)	0.46A	5y80A-5grnA: 22.5	5y80A-5grnA: 11.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 599 VAL A 607 ALA A 625 LYS A 627 GLU A 644 THR A 674 CYH A 677 GLY A 680	748 A1001 (-3.8A) 748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 (-4.0A) 748 A1001 (-3.3A) 748 A1001 (-3.2A) 748 A1001 (-4.5A) 748 A1001 ( 4.0A)	0.53A	5y80A-5grnA: 22.5	5y80A-5grnA: 11.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	8	LEU A 20 VAL A 28 ALA A 41 GLU A 61 LEU A 92 GLY A 96 LEU A 143 ASP A 157	ADP A 301 ( 4.0A) ADP A 301 (-3.7A) ADP A 301 (-3.5A) None ADP A 301 ( 4.8A) None ADP A 301 (-4.7A) MG A 302 ( 3.3A)	0.66A	5y80A-5hu3A: 26.3	5y80A-5hu3A: 15.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	8	LEU A 20 VAL A 28 ALA A 41 LYS A 43 GLU A 61 LEU A 92 GLY A 96 ASP A 157	ADP A 301 ( 4.0A) ADP A 301 (-3.7A) ADP A 301 (-3.5A) ADP A 301 (-2.7A) None ADP A 301 ( 4.8A) None MG A 302 ( 3.3A)	0.75A	5y80A-5hu3A: 26.3	5y80A-5hu3A: 15.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	9	LEU A 57 VAL A 65 ALA A 77 LYS A 79 GLU A 95 CYH A 133 GLY A 136 LEU A 187 ASP A 198	IDV A 401 (-3.8A) IDV A 401 (-4.6A) IDV A 401 (-3.6A) IDV A 401 ( 4.8A) None IDV A 401 (-4.6A) IDV A 401 (-3.4A) IDV A 401 (-4.4A) IDV A 401 (-4.0A)	0.72A	5y80A-5i3oA: 10.0	5y80A-5i3oA: 24.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 30 ALA A 43 LYS A 45 GLU A 61 CYH A 93 GLY A 96 LEU A 143 ASP A 154	6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) 6G2 A 901 ( 3.9A) None TPO A 145 (-4.1A) 6G2 A 901 (-3.6A) 6G2 A 901 (-4.7A) 6G2 A 901 (-3.4A)	0.46A	5y80A-5j5tA: 22.5	5y80A-5j5tA: 12.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5jzn	SERINE/THREONINE-PRO TEIN KINASE DCLK1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 404 ALA A 417 GLU A 436 LEU A 467 GLY A 471 LEU A 518 ASP A 533	GUI A 701 (-4.4A) GUI A 701 ( 3.9A) None GUI A 701 ( 4.7A) GUI A 701 (-3.6A) GUI A 701 (-4.4A) GUI A 701 ( 4.8A)	0.58A	5y80A-5jznA: 25.1	5y80A-5jznA: 14.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lxd	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 163 ALA A 176 LYS A 178 GLU A 193 LEU A 230 LEU A 282 ASP A 295	7A7 A 501 (-4.4A) 7A7 A 501 (-3.5A) 7A7 A 501 (-3.5A) 7A7 A 501 ( 4.7A) None 7A7 A 501 (-4.9A) 7A7 A 501 (-3.2A)	0.47A	5y80A-5lxdA: 22.9	5y80A-5lxdA: 12.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5tvt	MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (Homo sapiens)	no annotation	8	VAL A 25 ALA A 38 LYS A 40 GLU A 57 CYH A 89 GLY A 92 LEU A 139 ASP A 150	7LV A 401 ( 4.6A) 7LV A 401 (-3.4A) 7LV A 401 (-3.0A) 7LV A 401 (-3.5A) 7LV A 401 (-4.3A) None 7LV A 401 (-4.9A) 7LV A 401 (-4.2A)	0.75A	5y80A-5tvtA: 25.0	5y80A-5tvtA: 16.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	PF00069 (Pkinase)	9	LEU A 116 VAL A 124 ALA A 137 GLU A 157 THR A 187 LEU A 189 CYH A 190 GLY A 191 ASP A 251	H8H A 401 (-3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) None H8H A 401 (-3.5A) None H8H A 401 (-4.3A) H8H A 401 (-4.4A) EDO A 402 ( 2.9A)	0.82A	5y80A-5vcxA: 22.7	5y80A-5vcxA: 14.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	PF00069 (Pkinase)	9	LEU A 116 VAL A 124 ALA A 137 LYS A 139 GLU A 157 THR A 187 LEU A 189 CYH A 190 GLY A 191	H8H A 401 (-3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-4.9A) None H8H A 401 (-3.5A) None H8H A 401 (-4.3A) H8H A 401 (-4.4A)	0.93A	5y80A-5vcxA: 22.7	5y80A-5vcxA: 14.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vil	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5 (Homo sapiens)	no annotation	7	LEU A 686 VAL A 694 ALA A 707 GLU A 725 GLY A 760 LEU A 810 ASP A 822	9E1 A1001 (-3.7A) 9E1 A1001 ( 4.0A) 9E1 A1001 (-3.5A) None 9E1 A1001 (-3.4A) 9E1 A1001 (-4.5A) 9E1 A1001 (-3.6A)	0.60A	5y80A-5vilA: 23.1	5y80A-5vilA: 26.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b2q	SERINE/THREONINE-PRO TEIN KINASE PKNA (Mycobacterium tuberculosis)	no annotation	8	VAL A 27 ALA A 40 LYS A 42 GLU A 61 LEU A 97 GLY A 100 LEU A 148 ASP A 159	CJJ A 301 (-4.6A) CJJ A 301 (-3.5A) CJJ A 301 (-3.7A) None None CJJ A 301 (-4.2A) CJJ A 301 (-4.5A) CJJ A 301 (-4.3A)	0.99A	5y80A-6b2qA: 24.4	5y80A-6b2qA: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c0t	CGMP-DEPENDENT PROTEIN KINASE 1 (Homo sapiens)	no annotation	8	LEU A 366 VAL A 374 ALA A 388 LYS A 390 GLU A 409 CYH A 441 GLY A 444 ASP A 502	EE4 A 701 ( 4.6A) EE4 A 701 (-4.4A) EE4 A 701 (-3.3A) DMS A 702 (-3.5A) DMS A 702 ( 4.2A) EE4 A 701 (-4.6A) None DMS A 702 ( 3.1A)	0.85A	5y80A-6c0tA: 24.9	5y80A-6c0tA: 26.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cmj	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	8	VAL A 179 ALA A 192 LYS A 194 GLU A 236 LEU A 269 GLY A 273 LEU A 319 ASP A 330	F6J A 501 (-4.6A) F6J A 501 (-3.4A) F6J A 501 (-2.9A) F6J A 501 ( 4.7A) F6J A 501 ( 4.4A) F6J A 501 ( 3.7A) F6J A 501 (-4.5A) F6J A 501 (-3.8A)	0.65A	5y80A-6cmjA: 24.6	5y80A-6cmjA: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fyl	DUAL SPECIFICITY PROTEIN KINASE CLK2 (Homo sapiens)	no annotation	9	LEU A 169 VAL A 177 ALA A 191 LYS A 193 GLU A 208 LEU A 245 GLY A 247 LEU A 297 ASP A 327	3NG A 501 (-3.9A) 3NG A 501 ( 4.4A) 3NG A 501 (-3.3A) 3NG A 501 (-3.0A) 3NG A 501 ( 4.9A) 3NG A 501 ( 4.7A) None None 3NG A 501 (-4.5A)	0.92A	5y80A-6fylA: 24.3	5y80A-6fylA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fyo	DUAL SPECIFICITY PROTEIN KINASE CLK1 (Homo sapiens)	no annotation	8	LEU A 167 VAL A 175 ALA A 189 LYS A 191 LEU A 243 GLY A 245 LEU A 295 ASP A 325	EAQ A 501 (-3.9A) None EAQ A 501 (-3.6A) EAQ A 501 (-3.2A) EAQ A 501 ( 4.9A) EAQ A 501 (-3.9A) EAQ A 501 (-4.9A) EAQ A 501 (-4.6A)	1.00A	5y80A-6fyoA: 23.9	5y80A-6fyoA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fyv	DUAL SPECIFICITY PROTEIN KINASE CLK4 (Homo sapiens)	no annotation	9	LEU A 167 VAL A 175 ALA A 189 LYS A 191 GLU A 206 LEU A 243 GLY A 245 LEU A 295 ASP A 325	3NG A 501 (-3.9A) 3NG A 501 ( 4.3A) 3NG A 501 (-3.5A) 3NG A 501 (-2.7A) 3NG A 501 ( 4.7A) 3NG A 501 ( 4.7A) None None 3NG A 501 (-4.3A)	0.98A	5y80A-6fyvA: 24.1	5y80A-6fyvA: undetectable

[["5Y80_A_IREA401_0","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"VAL A 209;ALA A 220;GLU A 236;THR A 266;GLY A 272;LEU A 321;ASP A 332","None","0.63A","5y80A-1k9aA:23.8","5y80A-1k9aA:9.98"],["5Y80_A_IREA401_0","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.51A","5y80A-1opkA:22.8","5y80A-1opkA:10.27"],["5Y80_A_IREA401_0","1q8y","Saccharomyces cerevisiae","SR PROTEIN KINASE","PF00069(Pkinase)",8,"LEU A 164;VAL A 172;ALA A 185;LYS A 187;GLU A 202;GLY A 250;LEU A 301;ASP A 550","ADP A 810 ( 4.3A);ADP A 810 (-4.1A);ADP A 810 (-3.3A);ADP A 810 (-3.1A);None;None;ADP A 810 (-4.7A);ADP A 810 ( 3.0A)","0.95A","5y80A-1q8yA:23.1","5y80A-1q8yA:12.80"],["5Y80_A_IREA401_0","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",8,"LEU A 616;VAL A 624;ALA A 642;GLU A 661;CYH A 694;GLY A 697;LEU A 818;ASP A 829","None","0.75A","5y80A-1rjbA:20.8","5y80A-1rjbA:12.82"],["5Y80_A_IREA401_0","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",8,"LEU A 595;VAL A 603;ALA A 621;GLU A 640;THR A 670;CYH A 673;GLY A 676;LEU A 799","STI A   3 ( 3.8A);STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-3.6A);STI A   3 (-3.2A);STI A   3 (-4.5A);STI A   3 ( 3.8A);STI A   3 (-4.4A)","0.50A","5y80A-1t46A:22.6","5y80A-1t46A:12.54"],["5Y80_A_IREA401_0","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",8,"LEU A 595;VAL A 603;ALA A 621;LYS A 623;GLU A 640;THR A 670;CYH A 673;GLY A 676","STI A   3 ( 3.8A);STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-3.7A);STI A   3 (-3.6A);STI A   3 (-3.2A);STI A   3 (-4.5A);STI A   3 ( 3.8A)","0.59A","5y80A-1t46A:22.6","5y80A-1t46A:12.54"],["5Y80_A_IREA401_0","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",8,"LEU A 344;VAL A 352;ALA A 367;LYS A 369;GLU A 386;GLY A 420;LEU A 468;ASP A 479","STU A 100 (-3.8A);STU A 100 (-4.8A);STU A 100 (-3.2A);STU A 100 ( 4.7A);None;STU A 100 (-3.5A);STU A 100 (-4.5A);STU A 100 (-3.5A)","0.52A","5y80A-1u59A:23.7","5y80A-1u59A:12.50"],["5Y80_A_IREA401_0","1u5q","Rattus norvegicus","SERINE\/THREONINE PROTEIN KINASE TAO2","PF00069(Pkinase)",8,"VAL A  42;ALA A  55;LYS A  57;GLU A  76;CYH A 108;GLY A 110;LEU A 158;ASP A 169","None","0.55A","5y80A-1u5qA:24.4","5y80A-1u5qA:10.57"],["5Y80_A_IREA401_0","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",8,"LEU A  15;VAL A  23;ALA A  36;GLU A  55;CYH A  87;GLY A  90;LEU A 137;ASP A 148","HYM A 400 (-4.2A);HYM A 400 (-4.3A);HYM A 400 (-3.5A);None;HYM A 400 (-4.2A);None;HYM A 400 (-4.5A);HYM A 400 (-3.9A)","0.55A","5y80A-1zltA:23.1","5y80A-1zltA:12.20"],["5Y80_A_IREA401_0","2a2a","Homo sapiens","DEATH-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",7,"LEU A  19;VAL A  27;ALA A  40;LYS A  42;GLU A  64;LEU A  95;ASP A 161","None;None;GOL A3001 (-3.5A);None;None;None;None","0.63A","5y80A-2a2aA:25.9","5y80A-2a2aA:13.84"],["5Y80_A_IREA401_0","2buj","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 16","PF00069(Pkinase)",7,"LEU A  26;VAL A  34;ALA A  47;LYS A  49;GLU A  65;GLY A 104;LEU A 155","STU A1301 (-4.2A);STU A1301 (-4.8A);STU A1301 (-3.6A);STU A1301 ( 4.0A);None;STU A1301 ( 4.0A);STU A1301 ( 4.8A)","0.62A","5y80A-2bujA:29.7","5y80A-2bujA:11.71"],["5Y80_A_IREA401_0","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",9,"LEU X  17;VAL X  25;ALA X  37;LYS X  39;GLU X  54;THR X  82;GLY X  88;LEU X 137;ASP X 148","STU X 902 (-3.8A);STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-3.1A);STU X 902 ( 4.4A);STU X 902 (-4.1A);STU X 902 (-3.5A);STU X 902 (-4.4A);STU X 902 (-3.6A)","0.61A","5y80A-2dq7X:24.2","5y80A-2dq7X:16.02"],["5Y80_A_IREA401_0","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",9,"LEU A 162;VAL A 170;ALA A 184;LYS A 186;GLU A 201;LEU A 238;GLY A 240;LEU A 290;ASP A 320","None","0.88A","5y80A-2eu9A:24.5","5y80A-2eu9A:11.75"],["5Y80_A_IREA401_0","2gcd","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE TAO2","PF00069(Pkinase)",8,"VAL A  42;ALA A  55;LYS A  57;GLU A  76;CYH A 108;GLY A 110;LEU A 158;ASP A 169","STU A 400 ( 4.8A);STU A 400 (-3.2A);STU A 400 ( 4.5A);None;STU A 400 (-4.0A);STU A 400 (-3.4A);STU A 400 ( 4.6A);STU A 400 (-3.6A)","0.45A","5y80A-2gcdA:24.3","5y80A-2gcdA:9.55"],["5Y80_A_IREA401_0","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 273;VAL A 281;ALA A 293;THR A 338;GLY A 344;LEU A 393;ASP A 404","H8H A 534 (-3.8A);H8H A 534 (-4.4A);H8H A 534 (-3.2A);H8H A 534 (-3.1A);H8H A 534 (-3.3A);H8H A 534 (-4.5A);H8H A 534 (-4.2A)","0.63A","5y80A-2h8hA:21.7","5y80A-2h8hA:11.13"],["5Y80_A_IREA401_0","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",8,"LEU A 248;VAL A 256;ALA A 269;GLU A 286;THR A 315;GLY A 321;LEU A 370;ASP A 381","GIN A 600 ( 4.6A);GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.4A);None;GIN A 600 (-4.7A);GIN A 600 (-4.9A)","0.64A","5y80A-2hz0A:22.8","5y80A-2hz0A:14.61"],["5Y80_A_IREA401_0","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",8,"LEU A 248;VAL A 256;ALA A 269;LYS A 271;GLU A 286;THR A 315;GLY A 321;ASP A 381","GIN A 600 ( 4.6A);GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.6A);GIN A 600 (-3.4A);None;GIN A 600 (-4.9A)","0.78A","5y80A-2hz0A:22.8","5y80A-2hz0A:14.61"],["5Y80_A_IREA401_0","2j0j","Gallus gallus","FOCAL ADHESION KINASE 1","PF00373(FERM_M);PF07714(Pkinase_Tyr)",9,"VAL A 436;ALA A 452;LYS A 454;GLU A 471;LEU A 501;CYH A 502;GLY A 505;LEU A 553;ASP A 564","4ST A1687 ( 4.8A);4ST A1687 (-3.3A);4ST A1687 (-3.4A);4ST A1687 ( 4.6A);4ST A1687 (-4.3A);4ST A1687 (-4.1A);4ST A1687 (-3.2A);4ST A1687 (-4.4A);4ST A1687 (-4.7A)","0.60A","5y80A-2j0jA:23.2","5y80A-2j0jA:9.12"],["5Y80_A_IREA401_0","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",8,"LEU A 251;VAL A 259;ALA A 271;LYS A 273;GLU A 288;THR A 316;GLY A 322;LEU A 371","None;None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.4A);1N8 A 501 ( 3.6A);1N8 A 501 ( 3.3A);1N8 A 501 ( 3.5A);1N8 A 501 ( 4.3A)","0.85A","5y80A-2og8A:21.6","5y80A-2og8A:18.02"],["5Y80_A_IREA401_0","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",9,"LEU A 588;VAL A 596;ALA A 614;GLU A 633;THR A 663;CYH A 666;GLY A 669;LEU A 785;ASP A 796","None","0.86A","5y80A-2ogvA:21.2","5y80A-2ogvA:11.30"],["5Y80_A_IREA401_0","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",9,"LEU A  25;VAL A  33;ALA A  46;LYS A  48;GLU A  73;LEU A 105;GLY A 109;LEU A 156;ASP A 167","ATP A 381 ( 4.3A);ATP A 381 (-4.1A);ATP A 381 (-3.5A);ATP A 381 (-3.2A);None;None;None;ATP A 381 ( 4.8A); MN A 382 (-2.0A)","0.64A","5y80A-2phkA:27.1","5y80A-2phkA:14.34"],["5Y80_A_IREA401_0","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",8,"LEU A 724;VAL A 732;ALA A 749;THR A 796;LEU A 798;GLY A 802;LEU A 850;ASP A 861","GW7 A   1 ( 4.2A);GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-4.0A);GW7 A   1 (-4.5A);GW7 A   1 (-3.6A);GW7 A   1 (-4.2A);GW7 A   1 (-4.1A)","0.63A","5y80A-2r4bA:20.7","5y80A-2r4bA:12.19"],["5Y80_A_IREA401_0","2w4k","Homo sapiens","DEATH-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"LEU A  19;VAL A  27;ALA A  40;LYS A  42;GLU A  64;LEU A  95;ASP A 161","ADP A1303 ( 3.9A);ADP A1303 (-4.0A);ADP A1303 (-3.5A);ADP A1303 (-2.7A);ADP A1303 ( 4.8A);None; MG A1304 ( 2.8A)","0.55A","5y80A-2w4kA:25.8","5y80A-2w4kA:16.19"],["5Y80_A_IREA401_0","2wnt","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE","PF00069(Pkinase)",8,"ALA A 445;LYS A 447;GLU A 459;THR A 489;LEU A 491;GLY A 495;LEU A 542;ASP A 557","None","0.78A","5y80A-2wntA:22.0","5y80A-2wntA:13.70"],["5Y80_A_IREA401_0","2xik","Homo sapiens","SERINE\/THREONINE PROTEIN KINASE 25","PF00069(Pkinase)",7,"VAL A  34;ALA A  47;LYS A  49;GLU A  66;GLY A 101;LEU A 147;ASP A 158","J60 A1294 ( 4.9A);J60 A1294 (-3.3A);None;None;J60 A1294 ( 3.8A);J60 A1294 (-4.8A);J60 A1294 ( 4.6A)","0.62A","5y80A-2xikA:25.1","5y80A-2xikA:14.68"],["5Y80_A_IREA401_0","2yab","Mus musculus","DEATH-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",7,"LEU A  19;VAL A  27;ALA A  40;LYS A  42;GLU A  64;LEU A  95;ASP A 161","AMP A1302 (-3.7A);AMP A1302 (-4.2A);AMP A1302 (-3.6A);AMP A1302 (-2.8A);None;AMP A1302 ( 4.9A);AMP A1302 (-3.1A)","0.55A","5y80A-2yabA:26.1","5y80A-2yabA:13.84"],["5Y80_A_IREA401_0","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",7,"LEU A  68;VAL A  76;ALA A  92;LYS A  94;GLY A 147;LEU A 194;ASP A 205","STU A   1 (-3.8A);None;STU A   1 (-3.3A);STU A   1 (-2.8A);STU A   1 ( 3.9A);STU A   1 (-4.6A);STU A   1 ( 3.8A)","0.54A","5y80A-2z7rA:23.3","5y80A-2z7rA:16.11"],["5Y80_A_IREA401_0","3a62","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE BETA-1","PF00069(Pkinase)",7,"LEU A  97;VAL A 105;ALA A 121;LYS A 123;GLU A 143;GLY A 178;ASP A 236","STU A 400 (-3.8A);STU A 400 (-4.9A);STU A 400 (-3.1A);STU A 400 ( 4.3A);STU A 400 ( 4.3A);STU A 400 ( 4.4A);STU A 400 ( 3.8A)","0.60A","5y80A-3a62A:6.5","5y80A-3a62A:13.10"],["5Y80_A_IREA401_0","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 484;VAL A 492;ALA A 512;LYS A 514;GLU A 531;GLY A 567;LEU A 630;ASP A 641","C4F A   1 ( 3.9A);None;C4F A   1 (-3.3A);None;None;None;C4F A   1 (-4.6A);C4F A   1 (-4.5A)","0.81A","5y80A-3c4fA:21.6","5y80A-3c4fA:12.96"],["5Y80_A_IREA401_0","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",7,"VAL A 209;ALA A 220;GLU A 236;THR A 266;GLY A 272;LEU A 321;ASP A 332","None","0.63A","5y80A-3d7uA:24.4","5y80A-3d7uA:13.39"],["5Y80_A_IREA401_0","3hko","Cryptosporidium parvum","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 2 CALMODULIN-LIKE EF HANDS","PF00069(Pkinase)",8,"ALA A  37;LYS A  39;GLU A  60;LEU A  91;CYH A  92;GLY A  95;LEU A 182;ASP A 195","ANP A 329 ( 3.7A);ANP A 329 (-2.7A); MG A 330 ( 4.6A);ANP A 329 ( 4.7A);ANP A 329 (-4.1A);None;ANP A 329 (-4.4A); MG A 330 ( 2.9A)","1.11A","5y80A-3hkoA:23.6","5y80A-3hkoA:14.38"],["5Y80_A_IREA401_0","3hko","Cryptosporidium parvum","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 2 CALMODULIN-LIKE EF HANDS","PF00069(Pkinase)",8,"VAL A  24;ALA A  37;LYS A  39;GLU A  60;LEU A  91;CYH A  92;GLY A  94;LEU A 182","ANP A 329 (-4.4A);ANP A 329 ( 3.7A);ANP A 329 (-2.7A); MG A 330 ( 4.6A);ANP A 329 ( 4.7A);ANP A 329 (-4.1A);None;ANP A 329 (-4.4A)","1.12A","5y80A-3hkoA:23.6","5y80A-3hkoA:14.38"],["5Y80_A_IREA401_0","3hko","Cryptosporidium parvum","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 2 CALMODULIN-LIKE EF HANDS","PF00069(Pkinase)",8,"VAL A  24;ALA A  37;LYS A  39;GLU A  60;LEU A  91;CYH A  92;GLY A  95;LEU A 182","ANP A 329 (-4.4A);ANP A 329 ( 3.7A);ANP A 329 (-2.7A); MG A 330 ( 4.6A);ANP A 329 ( 4.7A);ANP A 329 (-4.1A);None;ANP A 329 (-4.4A)","1.07A","5y80A-3hkoA:23.6","5y80A-3hkoA:14.38"],["5Y80_A_IREA401_0","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 833;VAL A 841;ALA A 859;LYS A 861;GLU A 878;CYH A 912;GLY A 915;LEU A1029","8ST A2001 ( 4.7A);8ST A2001 ( 4.6A);8ST A2001 ( 3.8A);8ST A2001 (-4.0A);8ST A2001 (-3.7A);8ST A2001 (-3.8A);None;None","0.66A","5y80A-3hngA:22.0","5y80A-3hngA:14.10"],["5Y80_A_IREA401_0","3kn5","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-5","PF00069(Pkinase)",7,"LEU A 432;ALA A 453;LYS A 455;GLU A 468;LEU A 500;LEU A 551;ASP A 565","ANP A 400 (-4.1A);ANP A 400 ( 3.8A);None;None;ANP A 400 (-4.6A);ANP A 400 (-4.7A);None","0.62A","5y80A-3kn5A:22.1","5y80A-3kn5A:14.48"],["5Y80_A_IREA401_0","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",8,"VAL A 649;ALA A 665;LYS A 667;GLU A 684;THR A 713;GLY A 719;LEU A 767;ASP A 778","None;None;None;None;None;GOL A 403 (-3.4A);None;None","0.74A","5y80A-3kulA:24.4","5y80A-3kulA:12.62"],["5Y80_A_IREA401_0","3lj0","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE\/ENDORIBONUCLEASE IRE1","PF00069(Pkinase);PF06479(Ribonuc_2-5A)",8,"LEU A 680;VAL A 689;ALA A 700;GLU A 715;LEU A 747;CYH A 748;LEU A 804;ASP A 828","ADP A2101 ( 4.1A);ADP A2101 (-4.5A);ADP A2101 (-3.5A);None;None;ADP A2101 (-4.2A);ADP A2101 (-4.4A); SR A2103 (-2.6A)","0.78A","5y80A-3lj0A:24.1","5y80A-3lj0A:12.29"],["5Y80_A_IREA401_0","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",8,"VAL A 218;ALA A 229;LYS A 231;GLU A 244;THR A 279;GLY A 285;LEU A 339;ASP A 350","LDN A   1 ( 4.8A);LDN A   1 (-3.6A);None;None;LDN A   1 (-3.8A);LDN A   1 (-3.3A);LDN A   1 (-4.5A);LDN A   1 (-3.9A)","0.70A","5y80A-3mdyA:24.0","5y80A-3mdyA:14.02"],["5Y80_A_IREA401_0","3mvj","Homo sapiens","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase)",8,"LEU A  49;VAL A  57;ALA A  70;LYS A  72;GLU A  91;GLY A 126;LEU A 173;ASP A 184","XFE A 351 (-4.2A);XFE A 351 ( 4.5A);XFE A 351 (-3.2A);None;None;None;XFE A 351 (-4.6A);None","0.69A","5y80A-3mvjA:24.0","5y80A-3mvjA:12.40"],["5Y80_A_IREA401_0","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",8,"LEU A 192;VAL A 200;ALA A 213;LYS A 215;GLU A 234;LEU A 265;GLY A 269;ASP A 329","AMP A 577 ( 4.3A);AMP A 577 (-4.3A);AMP A 577 (-3.4A);AMP A 577 (-2.8A);None;AMP A 577 ( 4.9A);None;AMP A 577 (-4.0A)","0.88A","5y80A-3nyoA:23.9","5y80A-3nyoA:8.65"],["5Y80_A_IREA401_0","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",9,"LEU A 726;VAL A 734;ALA A 751;LYS A 753;THR A 798;LEU A 800;GLY A 804;LEU A 852;ASP A 863","03Q A   1 (-3.8A);03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.7A);03Q A   1 (-4.1A);03Q A   1 (-4.6A);03Q A   1 ( 3.9A);03Q A   1 (-4.4A);03Q A   1 (-4.0A)","0.78A","5y80A-3pp0A:21.6","5y80A-3pp0A:14.40"],["5Y80_A_IREA401_0","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",8,"VAL A 565;ALA A 576;LYS A 578;GLU A 596;THR A 625;GLY A 631;LEU A 683;ASP A 694","STU A   1 (-4.9A);STU A   1 (-3.3A);STU A   1 (-3.5A);None;STU A   1 (-4.1A);STU A   1 (-3.2A);STU A   1 (-4.3A);STU A   1 (-3.5A)","0.70A","5y80A-3ppzA:24.8","5y80A-3ppzA:13.96"],["5Y80_A_IREA401_0","3q5i","Plasmodium berghei","PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",8,"LEU A  63;VAL A  71;ALA A  84;GLU A 115;THR A 144;GLY A 150;LEU A 197;ASP A 211","ANP A1634 ( 4.3A);ANP A1634 (-4.1A);ANP A1634 (-3.6A);None;ANP A1634 (-4.6A);None;ANP A1634 (-4.4A); MG A 529 (-2.2A)","0.69A","5y80A-3q5iA:22.7","5y80A-3q5iA:10.61"],["5Y80_A_IREA401_0","3q5i","Plasmodium berghei","PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",8,"LEU A  63;VAL A  71;ALA A  84;LYS A  86;GLU A 115;GLY A 150;LEU A 197;ASP A 211","ANP A1634 ( 4.3A);ANP A1634 (-4.1A);ANP A1634 (-3.6A);ANP A1634 (-3.1A);None;None;ANP A1634 (-4.4A); MG A 529 (-2.2A)","0.77A","5y80A-3q5iA:22.7","5y80A-3q5iA:10.61"],["5Y80_A_IREA401_0","3she","Homo sapiens","MAP KINASE-ACTIVATED PROTEIN KINASE 3","PF00069(Pkinase)",8,"LEU A  50;VAL A  58;ALA A  71;LYS A  73;GLU A  84;GLY A 124;LEU A 173;ASP A 187","I85 A 350 (-3.7A);I85 A 350 (-4.9A);I85 A 350 (-3.3A);I85 A 350 (-2.8A);None;I85 A 350 (-3.0A);None;I85 A 350 (-3.3A)","0.80A","5y80A-3sheA:21.8","5y80A-3sheA:15.73"],["5Y80_A_IREA401_0","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 484;VAL A 492;ALA A 512;LYS A 514;GLU A 531;GLY A 567;LEU A 630;ASP A 641","07J A   1 ( 4.3A);07J A   1 (-4.0A);07J A   1 (-3.5A);07J A   1 (-4.5A);07J A   1 (-3.8A);07J A   1 (-3.7A);07J A   1 ( 4.4A);07J A   1 (-4.7A)","0.69A","5y80A-3tt0A:21.9","5y80A-3tt0A:13.42"],["5Y80_A_IREA401_0","3txo","Homo sapiens","PROTEIN KINASE C ETA TYPE","PF00069(Pkinase);PF00433(Pkinase_C)",8,"LEU A 361;VAL A 369;ALA A 382;LYS A 384;GLU A 403;GLY A 439;LEU A 486;ASP A 497","07U A   1 ( 4.8A);07U A   1 (-4.8A);07U A   1 (-3.3A);07U A   1 (-3.0A);07U A   1 ( 4.8A);None;07U A   1 (-4.3A);07U A   1 (-3.6A)","0.65A","5y80A-3txoA:23.6","5y80A-3txoA:12.87"],["5Y80_A_IREA401_0","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"LEU A 840;VAL A 848;ALA A 866;LYS A 868;GLU A 885;CYH A 919;GLY A 922;LEU A1035","4TT A2001 ( 4.0A);4TT A2001 ( 4.5A);4TT A2001 (-3.5A);None;None;4TT A2001 (-4.3A);4TT A2001 (-3.7A);4TT A2001 (-4.8A)","0.55A","5y80A-3vidA:21.0","5y80A-3vidA:12.96"],["5Y80_A_IREA401_0","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",9,"LEU A 840;VAL A 848;ALA A 866;LYS A 868;GLU A 885;CYH A 919;GLY A 922;LEU A1035;ASP A1046","LEV A1201 ( 3.8A);LEV A1201 ( 4.9A);LEV A1201 (-3.5A);None;LEV A1201 (-3.7A);LEV A1201 (-4.1A);LEV A1201 (-3.6A);LEV A1201 (-4.8A);GOL A1210 ( 3.4A)","0.74A","5y80A-3wzdA:21.3","5y80A-3wzdA:13.42"],["5Y80_A_IREA401_0","4a4l","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PLK1","PF00069(Pkinase)",7,"LEU A  59;ALA A  80;LYS A  82;GLU A 101;LEU A 132;CYH A 133;ASP A 194","939 A1331 (-3.7A);939 A1331 (-3.5A);939 A1331 (-2.6A);None;939 A1331 (-4.4A);939 A1331 (-4.0A);939 A1331 (-3.1A)","0.62A","5y80A-4a4lA:27.9","5y80A-4a4lA:12.54"],["5Y80_A_IREA401_0","4aw2","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE MRCK ALPHA","PF00069(Pkinase);PF00433(Pkinase_C)",7,"VAL A  91;ALA A 104;LYS A 106;GLU A 125;GLY A 160;LEU A 208;ASP A 219","None;EDO A1420 (-3.4A);EDO A1419 (-3.3A);EDO A1419 (-3.0A);None;EDO A1420 ( 4.8A);None","0.58A","5y80A-4aw2A:23.8","5y80A-4aw2A:11.82"],["5Y80_A_IREA401_0","4c0t","Candida albicans","LIKELY PROTEIN KINASE","PF00069(Pkinase)",8,"LEU A 246;VAL A 254;ALA A 267;LYS A 269;GLU A 288;GLY A 324;LEU A 371;ASP A 382","None","0.73A","5y80A-4c0tA:25.8","5y80A-4c0tA:6.40"],["5Y80_A_IREA401_0","4cfh","Rattus norvegicus","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1","PF00069(Pkinase);PF16579(AdenylateSensor)",7,"VAL A  30;ALA A  43;LYS A  45;GLU A  64;GLY A  99;LEU A 146;ASP A 157","None;STU A1550 (-3.1A);STU A1550 (-3.6A);None;STU A1550 (-3.4A);STU A1550 (-4.3A);STU A1550 (-3.6A)","0.61A","5y80A-4cfhA:25.6","5y80A-4cfhA:9.74"],["5Y80_A_IREA401_0","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 616;VAL A 624;ALA A 653;LYS A 655;GLU A 672;THR A 701;GLY A 707;LEU A 773","None;DI1 A1000 (-4.8A);DI1 A1000 (-3.6A);DI1 A1000 (-3.9A);DI1 A1000 (-3.8A);DI1 A1000 (-3.6A);None;DI1 A1000 (-4.5A)","0.73A","5y80A-4ckrA:21.9","5y80A-4ckrA:13.36"],["5Y80_A_IREA401_0","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",8,"LEU A 663;VAL A 671;ALA A 684;LYS A 686;GLU A 705;GLY A 743;LEU A 789;ASP A 800","AGS A1985 (-4.2A);AGS A1985 (-4.6A);AGS A1985 (-3.5A);AGS A1985 (-3.0A);None;None;AGS A1985 (-4.8A);AGS A1985 ( 3.3A)","0.66A","5y80A-4crsA:25.8","5y80A-4crsA:12.32"],["5Y80_A_IREA401_0","4eut","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TBK1","PF00069(Pkinase)",8,"LEU A  15;VAL A  23;ALA A  36;LYS A  38;GLU A  55;CYH A  89;GLY A  92;ASP A 157","BX7 A 401 (-3.7A);BX7 A 401 (-4.4A);BX7 A 401 (-3.4A);BX7 A 401 ( 4.0A);None;BX7 A 401 (-4.1A);BX7 A 401 (-3.5A);BX7 A 401 ( 3.7A)","0.72A","5y80A-4eutA:20.6","5y80A-4eutA:12.44"],["5Y80_A_IREA401_0","4euu","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TBK1","PF00069(Pkinase)",8,"LEU A  15;VAL A  23;ALA A  36;LYS A  38;GLU A  55;CYH A  89;GLY A  92;ASP A 157","BX7 A 401 (-3.9A);BX7 A 401 ( 4.6A);BX7 A 401 (-3.4A);BX7 A 401 (-3.5A);None;BX7 A 401 (-4.1A);BX7 A 401 (-3.3A);BX7 A 401 (-3.6A)","0.60A","5y80A-4euuA:22.6","5y80A-4euuA:15.95"],["5Y80_A_IREA401_0","4fod","Homo sapiens","ALK TYROSINE KINASE RECEPTOR","PF07714(Pkinase_Tyr)",8,"LEU A1122;VAL A1130;ALA A1148;GLU A1167;LEU A1198;GLY A1202;LEU A1256;ASP A1270","0UV A1501 (-3.8A);0UV A1501 (-4.5A);0UV A1501 (-3.4A);None;0UV A1501 ( 4.8A);0UV A1501 (-3.6A);0UV A1501 (-4.6A);0UV A1501 ( 4.2A)","0.90A","5y80A-4fodA:22.2","5y80A-4fodA:11.71"],["5Y80_A_IREA401_0","4fr4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 32A","PF00069(Pkinase)",8,"VAL A  37;ALA A  50;LYS A  52;GLU A  71;LEU A 102;GLY A 106;LEU A 153;ASP A 164","STU A 401 ( 4.9A);STU A 401 (-3.2A);None;None;STU A 401 (-4.4A);STU A 401 ( 3.7A);STU A 401 (-4.7A);STU A 401 ( 3.9A)","0.55A","5y80A-4fr4A:23.6","5y80A-4fr4A:13.68"],["5Y80_A_IREA401_0","4g3f","Mus musculus","NF-KAPPA-BETA-INDUCING KINASE","PF00069(Pkinase)",8,"VAL A 416;ALA A 429;LYS A 431;GLU A 442;LEU A 473;GLY A 477;LEU A 524;ASP A 536","0WB A 701 (-4.4A);0WB A 701 (-3.3A);0WB A 701 (-3.0A);0WB A 701 (-3.2A);0WB A 701 (-4.3A);0WB A 701 ( 4.5A);0WB A 701 (-4.3A);0WB A 701 (-3.1A)","0.65A","5y80A-4g3fA:21.2","5y80A-4g3fA:15.85"],["5Y80_A_IREA401_0","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",8,"LEU A 855;VAL A 863;ALA A 880;LYS A 882;GLU A 898;GLY A 935;LEU A 983;ASP A 994","IZA A2001 (-3.7A);None;IZA A2001 (-3.4A);IZA A2001 ( 4.7A);None;IZA A2001 (-3.3A);IZA A2001 ( 4.7A);IZA A2001 ( 4.5A)","0.76A","5y80A-4gl9A:24.3","5y80A-4gl9A:15.25"],["5Y80_A_IREA401_0","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",8,"LEU A 828;VAL A 836;ALA A 853;LYS A 855;GLU A 871;GLY A 908;LEU A 956;ASP A 967","19S A1201 (-3.9A);19S A1201 (-4.4A);19S A1201 (-3.3A);19S A1201 (-3.5A);None;19S A1201 ( 3.8A);19S A1201 (-4.5A);19S A1201 ( 4.1A)","0.67A","5y80A-4hviA:24.2","5y80A-4hviA:16.84"],["5Y80_A_IREA401_0","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",8,"LEU A 132;VAL A 140;ALA A 156;THR A 205;LEU A 207;GLY A 211;LEU A 259;ASP A 270","None","0.80A","5y80A-4hzsA:19.9","5y80A-4hzsA:14.11"],["5Y80_A_IREA401_0","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",7,"LEU A 132;VAL A 140;ALA A 156;THR A 205;LEU A 207;GLY A 211;LEU A 259","1G0 A 401 ( 4.5A);1G0 A 401 (-4.4A);1G0 A 401 (-3.6A);1G0 A 401 (-3.2A);1G0 A 401 ( 4.9A);1G0 A 401 ( 4.5A);1G0 A 401 (-4.6A)","0.62A","5y80A-4id7A:23.8","5y80A-4id7A:14.23"],["5Y80_A_IREA401_0","4idt","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14","PF00069(Pkinase)",8,"LEU A 406;VAL A 414;ALA A 427;GLU A 440;LEU A 471;GLY A 475;LEU A 522;ASP A 534","T28 A 701 (-3.8A);T28 A 701 (-4.7A);T28 A 701 (-3.0A);None;T28 A 701 ( 4.8A);T28 A 701 ( 3.0A);T28 A 701 (-3.9A);T28 A 701 ( 3.4A)","0.80A","5y80A-4idtA:21.5","5y80A-4idtA:13.48"],["5Y80_A_IREA401_0","4idt","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14","PF00069(Pkinase)",8,"LEU A 406;VAL A 414;ALA A 427;LYS A 429;GLU A 440;LEU A 471;GLY A 475;ASP A 534","T28 A 701 (-3.8A);T28 A 701 (-4.7A);T28 A 701 (-3.0A);T28 A 701 ( 3.8A);None;T28 A 701 ( 4.8A);T28 A 701 ( 3.0A);T28 A 701 ( 3.4A)","0.99A","5y80A-4idtA:21.5","5y80A-4idtA:13.48"],["5Y80_A_IREA401_0","4jlc","Mus musculus","SERINE\/THREONINE-PROTEIN KINASE TBK1","PF00069(Pkinase)",7,"LEU A  15;VAL A  23;ALA A  36;LYS A  38;CYH A  89;GLY A  92;ASP A 157","SU6 A 701 (-3.6A);None;SU6 A 701 (-3.4A);None;SU6 A 701 (-3.8A);SU6 A 701 (-3.8A);None","0.54A","5y80A-4jlcA:6.0","5y80A-4jlcA:7.91"],["5Y80_A_IREA401_0","4jxf","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PLK4","PF00069(Pkinase)",7,"LEU A  18;VAL A  26;ALA A  39;LYS A  41;CYH A  92;GLY A  95;LEU A 143","631 A 301 (-3.4A);631 A 301 (-4.6A);631 A 301 (-3.3A);631 A 301 (-2.7A);631 A 301 (-4.5A);631 A 301 ( 3.7A);631 A 301 (-4.0A)","0.53A","5y80A-4jxfA:18.8","5y80A-4jxfA:12.92"],["5Y80_A_IREA401_0","4mvf","Plasmodium falciparum","CALCIUM-DEPENDENT PROTEIN KINASE 2","PF00069(Pkinase);PF13499(EF-hand_7)",10,"LEU A  78;VAL A  86;ALA A  99;LYS A 101;GLU A 117;LEU A 148;CYH A 149;GLY A 151;LEU A 199;ASP A 213","STU A 601 ( 4.0A);STU A 601 (-4.8A);STU A 601 (-3.3A);STU A 601 (-3.9A);None;STU A 601 (-4.3A);STU A 601 (-4.2A);STU A 601 (-3.4A);STU A 601 (-4.7A);STU A 601 (-4.3A)","0.88A","5y80A-4mvfA:23.0","5y80A-4mvfA:11.61"],["5Y80_A_IREA401_0","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",9,"ALA A  67;GLU A  85;THR A 123;LEU A 125;CYH A 126;GLY A 128;GLN A 129;LEU A 180;ASP A 191","SIN A 401 ( 3.7A);None;None;SIN A 401 ( 4.8A);SIN A 401 (-4.3A);SIN A 401 (-3.5A);None;SIN A 401 ( 4.5A);None","0.67A","5y80A-4o38A:34.1","5y80A-4o38A:90.91"],["5Y80_A_IREA401_0","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",10,"LEU A  46;VAL A  54;ALA A  67;GLU A  85;THR A 123;LEU A 125;CYH A 126;GLY A 128;LEU A 180;ASP A 191","SIN A 401 ( 3.9A);None;SIN A 401 ( 3.7A);None;None;SIN A 401 ( 4.8A);SIN A 401 (-4.3A);SIN A 401 (-3.5A);SIN A 401 ( 4.5A);None","0.47A","5y80A-4o38A:34.1","5y80A-4o38A:90.91"],["5Y80_A_IREA401_0","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",10,"LEU A  46;VAL A  54;ALA A  67;LYS A  69;GLU A  85;THR A 123;LEU A 125;CYH A 126;GLY A 128;ASP A 191","SIN A 401 ( 3.9A);None;SIN A 401 ( 3.7A);None;None;None;SIN A 401 ( 4.8A);SIN A 401 (-4.3A);SIN A 401 (-3.5A);None","0.57A","5y80A-4o38A:34.1","5y80A-4o38A:90.91"],["5Y80_A_IREA401_0","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",8,"LEU A 903;VAL A 911;ALA A 928;LYS A 930;GLU A 947;GLY A 984;LEU A1030;ASP A1041","2TT A1202 (-3.5A);2TT A1202 (-4.5A);2TT A1202 ( 3.9A);None;None;2TT A1202 (-3.4A);2TT A1202 (-4.4A);2TT A1202 (-4.6A)","0.72A","5y80A-4oliA:6.3","5y80A-4oliA:8.52"],["5Y80_A_IREA401_0","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"LEU A 616;VAL A 624;ALA A 642;GLU A 661;CYH A 694;GLY A 697;LEU A 818","P30 A1001 (-3.8A);None;P30 A1001 (-3.4A);P30 A1001 (-3.6A);None;P30 A1001 (-3.4A);P30 A1001 (-4.6A)","0.49A","5y80A-4rt7A:22.3","5y80A-4rt7A:10.54"],["5Y80_A_IREA401_0","4wb7","Homo sapiens","DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase);PF00226(DnaJ)",8,"LEU A 104;VAL A 112;ALA A 125;LYS A 127;GLU A 146;GLY A 181;LEU A 228;ASP A 239","ATP A 501 ( 4.3A);ATP A 501 (-4.0A);ATP A 501 (-3.4A);ATP A 501 (-2.6A);None;None;ATP A 501 (-4.5A); ZN A 503 (-1.9A)","0.68A","5y80A-4wb7A:24.3","5y80A-4wb7A:12.06"],["5Y80_A_IREA401_0","4wsq","Homo sapiens","AP2-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",9,"LEU A  52;VAL A  60;ALA A  72;LYS A  74;CYH A 129;GLY A 132;GLN A 133;LEU A 183;ASP A 194","KSA A 405 ( 4.0A);KSA A 405 ( 4.9A);KSA A 405 (-3.2A);None;KSA A 405 (-4.5A);KSA A 405 (-3.5A);KSA A 405 (-3.2A);KSA A 405 (-4.6A); ZN A 403 ( 2.6A)","0.81A","5y80A-4wsqA:32.5","5y80A-4wsqA:25.58"],["5Y80_A_IREA401_0","4wsq","Homo sapiens","AP2-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",9,"LEU A  52;VAL A  60;ALA A  72;LYS A  74;GLU A  90;CYH A 129;GLY A 132;LEU A 183;ASP A 194","KSA A 405 ( 4.0A);KSA A 405 ( 4.9A);KSA A 405 (-3.2A);None;None;KSA A 405 (-4.5A);KSA A 405 (-3.5A);KSA A 405 (-4.6A); ZN A 403 ( 2.6A)","0.67A","5y80A-4wsqA:32.5","5y80A-4wsqA:25.58"],["5Y80_A_IREA401_0","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",8,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;GLU A 661;CYH A 694;GLY A 697;LEU A 818","P30 A1001 (-4.0A);P30 A1001 ( 4.8A);P30 A1001 (-3.5A);P30 A1001 ( 4.0A);P30 A1001 (-3.1A);P30 A1001 (-4.2A);P30 A1001 (-3.5A);P30 A1001 (-4.3A)","0.63A","5y80A-4xufA:21.9","5y80A-4xufA:12.01"],["5Y80_A_IREA401_0","4yff","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TNNI3K","PF07714(Pkinase_Tyr)",7,"VAL A 477;ALA A 488;LYS A 490;GLU A 509;THR A 539;GLY A 545;LEU A 595","None;4CV A 801 (-3.5A);4CV A 801 (-3.9A);None;4CV A 801 (-2.8A);4CV A 801 ( 4.0A);4CV A 801 (-4.4A)","0.59A","5y80A-4yffA:23.2","5y80A-4yffA:12.22"],["5Y80_A_IREA401_0","4ysj","Eimeria tenella","CALMODULIN-LIKE DOMAIN PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",9,"LEU A  34;VAL A  42;ALA A  55;LYS A  57;GLU A  76;THR A 105;GLY A 111;LEU A 158;ASP A 172","ADP A 506 ( 3.8A);ADP A 506 (-4.3A);ADP A 506 (-3.3A);ADP A 506 (-2.4A);None;ADP A 506 ( 4.6A);None;ADP A 506 (-4.7A);ADP A 506 ( 2.4A)","0.84A","5y80A-4ysjA:25.1","5y80A-4ysjA:12.14"],["5Y80_A_IREA401_0","5ezr","Plasmodium vivax","CGMP-DEPENDENT PROTEIN KINASE, PUTATIVE","PF00027(cNMP_binding);PF00069(Pkinase)",7,"VAL A 548;ALA A 561;LYS A 563;THR A 611;LEU A 613;LEU A 664;ASP A 675","4ZS A 901 (-4.8A);4ZS A 901 ( 3.8A);4ZS A 901 (-3.9A);4ZS A 901 (-3.2A);4ZS A 901 (-4.7A);4ZS A 901 (-3.6A);None","0.57A","5y80A-5ezrA:23.5","5y80A-5ezrA:7.74"],["5Y80_A_IREA401_0","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",8,"LEU A 903;VAL A 911;ALA A 928;LYS A 930;GLU A 947;GLY A 984;LEU A1030;ASP A1041","5U3 A1200 (-3.8A);5U3 A1200 ( 4.4A);5U3 A1200 (-3.5A);None;None;5U3 A1200 (-3.2A);5U3 A1200 (-4.4A);5U3 A1200 ( 4.9A)","0.85A","5y80A-5f1zA:22.7","5y80A-5f1zA:14.68"],["5Y80_A_IREA401_0","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",8,"LEU A 599;VAL A 607;ALA A 625;GLU A 644;THR A 674;CYH A 677;GLY A 680;LEU A 825","748 A1001 (-3.8A);748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 (-3.3A);748 A1001 (-3.2A);748 A1001 (-4.5A);748 A1001 ( 4.0A);748 A1001 (-4.3A)","0.46A","5y80A-5grnA:22.5","5y80A-5grnA:11.90"],["5Y80_A_IREA401_0","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",8,"LEU A 599;VAL A 607;ALA A 625;LYS A 627;GLU A 644;THR A 674;CYH A 677;GLY A 680","748 A1001 (-3.8A);748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 (-4.0A);748 A1001 (-3.3A);748 A1001 (-3.2A);748 A1001 (-4.5A);748 A1001 ( 4.0A)","0.53A","5y80A-5grnA:22.5","5y80A-5grnA:11.90"],["5Y80_A_IREA401_0","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",8,"LEU A  20;VAL A  28;ALA A  41;GLU A  61;LEU A  92;GLY A  96;LEU A 143;ASP A 157","ADP A 301 ( 4.0A);ADP A 301 (-3.7A);ADP A 301 (-3.5A);None;ADP A 301 ( 4.8A);None;ADP A 301 (-4.7A); MG A 302 ( 3.3A)","0.66A","5y80A-5hu3A:26.3","5y80A-5hu3A:15.05"],["5Y80_A_IREA401_0","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",8,"LEU A  20;VAL A  28;ALA A  41;LYS A  43;GLU A  61;LEU A  92;GLY A  96;ASP A 157","ADP A 301 ( 4.0A);ADP A 301 (-3.7A);ADP A 301 (-3.5A);ADP A 301 (-2.7A);None;ADP A 301 ( 4.8A);None; MG A 302 ( 3.3A)","0.75A","5y80A-5hu3A:26.3","5y80A-5hu3A:15.05"],["5Y80_A_IREA401_0","5i3o","Homo sapiens","BMP-2-INDUCIBLE PROTEIN KINASE","PF00069(Pkinase)",9,"LEU A  57;VAL A  65;ALA A  77;LYS A  79;GLU A  95;CYH A 133;GLY A 136;LEU A 187;ASP A 198","IDV A 401 (-3.8A);IDV A 401 (-4.6A);IDV A 401 (-3.6A);IDV A 401 ( 4.8A);None;IDV A 401 (-4.6A);IDV A 401 (-3.4A);IDV A 401 (-4.4A);IDV A 401 (-4.0A)","0.72A","5y80A-5i3oA:10.0","5y80A-5i3oA:24.22"],["5Y80_A_IREA401_0","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",8,"VAL A  30;ALA A  43;LYS A  45;GLU A  61;CYH A  93;GLY A  96;LEU A 143;ASP A 154","6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);6G2 A 901 ( 3.9A);None;TPO A 145 (-4.1A);6G2 A 901 (-3.6A);6G2 A 901 (-4.7A);6G2 A 901 (-3.4A)","0.46A","5y80A-5j5tA:22.5","5y80A-5j5tA:12.32"],["5Y80_A_IREA401_0","5jzn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE DCLK1","PF00069(Pkinase)",7,"VAL A 404;ALA A 417;GLU A 436;LEU A 467;GLY A 471;LEU A 518;ASP A 533","GUI A 701 (-4.4A);GUI A 701 ( 3.9A);None;GUI A 701 ( 4.7A);GUI A 701 (-3.6A);GUI A 701 (-4.4A);GUI A 701 ( 4.8A)","0.58A","5y80A-5jznA:25.1","5y80A-5jznA:14.65"],["5Y80_A_IREA401_0","5lxd","Homo sapiens","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 2","PF00069(Pkinase)",7,"VAL A 163;ALA A 176;LYS A 178;GLU A 193;LEU A 230;LEU A 282;ASP A 295","7A7 A 501 (-4.4A);7A7 A 501 (-3.5A);7A7 A 501 (-3.5A);7A7 A 501 ( 4.7A);None;7A7 A 501 (-4.9A);7A7 A 501 (-3.2A)","0.47A","5y80A-5lxdA:22.9","5y80A-5lxdA:12.06"],["5Y80_A_IREA401_0","5tvt","Homo sapiens","MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE","no annotation",8,"VAL A  25;ALA A  38;LYS A  40;GLU A  57;CYH A  89;GLY A  92;LEU A 139;ASP A 150","7LV A 401 ( 4.6A);7LV A 401 (-3.4A);7LV A 401 (-3.0A);7LV A 401 (-3.5A);7LV A 401 (-4.3A);None;7LV A 401 (-4.9A);7LV A 401 (-4.2A)","0.75A","5y80A-5tvtA:25.0","5y80A-5tvtA:16.38"],["5Y80_A_IREA401_0","5vcx","Homo sapiens","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","PF00069(Pkinase)",9,"LEU A 116;VAL A 124;ALA A 137;GLU A 157;THR A 187;LEU A 189;CYH A 190;GLY A 191;ASP A 251","H8H A 401 (-3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);None;H8H A 401 (-3.5A);None;H8H A 401 (-4.3A);H8H A 401 (-4.4A);EDO A 402 ( 2.9A)","0.82A","5y80A-5vcxA:22.7","5y80A-5vcxA:14.00"],["5Y80_A_IREA401_0","5vcx","Homo sapiens","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","PF00069(Pkinase)",9,"LEU A 116;VAL A 124;ALA A 137;LYS A 139;GLU A 157;THR A 187;LEU A 189;CYH A 190;GLY A 191","H8H A 401 (-3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-4.9A);None;H8H A 401 (-3.5A);None;H8H A 401 (-4.3A);H8H A 401 (-4.4A)","0.93A","5y80A-5vcxA:22.7","5y80A-5vcxA:14.00"],["5Y80_A_IREA401_0","5vil","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5","no annotation",7,"LEU A 686;VAL A 694;ALA A 707;GLU A 725;GLY A 760;LEU A 810;ASP A 822","9E1 A1001 (-3.7A);9E1 A1001 ( 4.0A);9E1 A1001 (-3.5A);None;9E1 A1001 (-3.4A);9E1 A1001 (-4.5A);9E1 A1001 (-3.6A)","0.60A","5y80A-5vilA:23.1","5y80A-5vilA:26.51"],["5Y80_A_IREA401_0","6b2q","Mycobacterium tuberculosis","SERINE\/THREONINE-PROTEIN KINASE PKNA","no annotation",8,"VAL A  27;ALA A  40;LYS A  42;GLU A  61;LEU A  97;GLY A 100;LEU A 148;ASP A 159","CJJ A 301 (-4.6A);CJJ A 301 (-3.5A);CJJ A 301 (-3.7A);None;None;CJJ A 301 (-4.2A);CJJ A 301 (-4.5A);CJJ A 301 (-4.3A)","0.99A","5y80A-6b2qA:24.4","5y80A-6b2qA:28.57"],["5Y80_A_IREA401_0","6c0t","Homo sapiens","CGMP-DEPENDENT PROTEIN KINASE 1","no annotation",8,"LEU A 366;VAL A 374;ALA A 388;LYS A 390;GLU A 409;CYH A 441;GLY A 444;ASP A 502","EE4 A 701 ( 4.6A);EE4 A 701 (-4.4A);EE4 A 701 (-3.3A);DMS A 702 (-3.5A);DMS A 702 ( 4.2A);EE4 A 701 (-4.6A);None;DMS A 702 ( 3.1A)","0.85A","5y80A-6c0tA:24.9","5y80A-6c0tA:26.37"],["5Y80_A_IREA401_0","6cmj","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",8,"VAL A 179;ALA A 192;LYS A 194;GLU A 236;LEU A 269;GLY A 273;LEU A 319;ASP A 330","F6J A 501 (-4.6A);F6J A 501 (-3.4A);F6J A 501 (-2.9A);F6J A 501 ( 4.7A);F6J A 501 ( 4.4A);F6J A 501 ( 3.7A);F6J A 501 (-4.5A);F6J A 501 (-3.8A)","0.65A","5y80A-6cmjA:24.6","5y80A-6cmjA:25.00"],["5Y80_A_IREA401_0","6fyl","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK2","no annotation",9,"LEU A 169;VAL A 177;ALA A 191;LYS A 193;GLU A 208;LEU A 245;GLY A 247;LEU A 297;ASP A 327","3NG A 501 (-3.9A);3NG A 501 ( 4.4A);3NG A 501 (-3.3A);3NG A 501 (-3.0A);3NG A 501 ( 4.9A);3NG A 501 ( 4.7A);None;None;3NG A 501 (-4.5A)","0.92A","5y80A-6fylA:24.3","5y80A-6fylA:undetectable"],["5Y80_A_IREA401_0","6fyo","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK1","no annotation",8,"LEU A 167;VAL A 175;ALA A 189;LYS A 191;LEU A 243;GLY A 245;LEU A 295;ASP A 325","EAQ A 501 (-3.9A);None;EAQ A 501 (-3.6A);EAQ A 501 (-3.2A);EAQ A 501 ( 4.9A);EAQ A 501 (-3.9A);EAQ A 501 (-4.9A);EAQ A 501 (-4.6A)","1.00A","5y80A-6fyoA:23.9","5y80A-6fyoA:undetectable"],["5Y80_A_IREA401_0","6fyv","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK4","no annotation",9,"LEU A 167;VAL A 175;ALA A 189;LYS A 191;GLU A 206;LEU A 243;GLY A 245;LEU A 295;ASP A 325","3NG A 501 (-3.9A);3NG A 501 ( 4.3A);3NG A 501 (-3.5A);3NG A 501 (-2.7A);3NG A 501 ( 4.7A);3NG A 501 ( 4.7A);None;None;3NG A 501 (-4.3A)","0.98A","5y80A-6fyvA:24.1","5y80A-6fyvA:undetectable"]]